[1] ZONIBERISSO M, FILIPPI A, LANDOLINA M, et al. Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian survey of Atrial Fibrillation Management[ISAF] study)[J]. AM J Cardiol, 2013, 111(5): 705-711.
[2] 胡大一, 孙艺红, 周自强, 等. 中国人非瓣膜性心房颤动脑卒中危险因素的病例对照研究[J]. 中华内科杂志, 2004, 42(3):157-161.
[3] LIP G, LANE D A. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?[J]. Am J Med, 2010, 123(9): 785-789.
[4] 马彩艳, 谢培怡, 张伟, 等. 高龄高出血风险心房颤动患者的超低强度华法林抗凝治疗分析[J]. 心电与循环, 2015, 34(1): 25-27.
[5] 张澍, 陈柯萍. 关于心房颤动抗凝治疗中的几个问题[J]. 中国循环杂志, 2002, 17(6): 472-472.
[6] 张鹤萍, 胡大一.非心瓣膜疾病性心房颤动与血栓栓塞[J]. 中华心血管病杂志, 2005, 33(10): 966-968.
[7] 王继霞, 陆俊. 阵发性室上性心动过速80例[J]. 临床医学, 2011,31(9):38-39.
[8] GUO Y, WU Q, ZHANG L. Antithrombotic therapy in very elderly patients with atrial fibrillation: Is it enough to assess thromboembolic risk?[J]. Clin Intervn Aging, 2010, 5: 157-162. |
